1 / 16

Prospettive di Health Economics nell ’ ottimizzazione CRT CRT optimization benefits: a Health Economics perspective

Prospettive di Health Economics nell ’ ottimizzazione CRT CRT optimization benefits: a Health Economics perspective. Dr Marcello Piacenti Fondazione Toscana G. Monasterio Istituto di Fisiologia Clinica C.N.R., Pisa . Città della Scienza, Napoli 12 e 13 aprile 2013.

uriel
Download Presentation

Prospettive di Health Economics nell ’ ottimizzazione CRT CRT optimization benefits: a Health Economics perspective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prospettive di Health Economicsnell’ottimizzazione CRTCRT optimization benefits:a Health Economics perspective Dr Marcello Piacenti Fondazione Toscana G. Monasterio Istituto di Fisiologia Clinica C.N.R., Pisa Città della Scienza, Napoli 12 e 13 aprile 2013

  2. Medical economics is a discipline that provides conceptual and quantitative tools to address the problem of allocating scarce resources efficiently • Any resources committed to health care are no longer available to other uses • For the economist, cost is not an amount of money but rather the consumption of societal resources that are lost to any other use. Heart Failure Clin 2013;9:93-106

  3. Cost-effectiveness analysis Cost-effectiveness analysis is a method of comparing incremental benefits and costs • Cost-effectiveness is measured in incremental terms and therefore requires the identification of an appropriate comparator • A therapy must be effective before it can be cost-effective • Because both costs and outcomes of a disease change with time, a cost-effectiveness study must capture all relevant costs and outcomes over the relevant time horizon

  4. Two types of cost-effectiveness analysis are performed • Based on randomized clinical trials (RCT): • cost and outcomes are prospectively collected with clinical data (QALYs) • characteristics of the pts recruited, selected centers performing the study, short follow-up • Based on decision-analytical modeling (DAM): • investigators design a mathematical model to recreate the natural history of the disease • permits to test the robustness of the results by subjecting the model to rigorous sensitivity analyses in which 1 or more input parameters are varied to test how this influences the reported results

  5. Considered Parameters • Analysis of outcome • QALYs (Quality Adjusted Life Years) • Analysis of cost/effectiveness • ICER (Incremental Cost-Effectiveness Ratio) QALYs = years x QoL ICER = C1-C2/E1-E2 C = cost E = QALYs gained or lost

  6. A hypothetical scenario to demonstrate the impact of the analytical time horizon on incremental costeffectiveness. (A) Cumulative costs, US Dollars. (B) Cumulative outcomes (quality-adjusted life years, QALYs). (C) Incremental cost-effectiveness ratio (ICER) at various time points (US Dollars per QALY).

  7. Willingness To Pay (WTP)

  8. J Am Coll Cardiol, 2009; 53:765-773, doi:10.1016/j.jacc.2008.11.024

  9. Europace Advance Access published March 2013 At 1 year: 25% deaths or hospitalizations for HF within the group of pts not systematically optimized (group 2) 9% deaths or hospitalizations for HF within the group of pts systematically optimized (SonR or Echo) (group 1) Reduction of 65% of HF hospitalization with systematic AV delay optimization with sonR at 1 years F-U

  10. Banz et al 2005: Input parameters

  11. Economical aspects of AV-delay optimization in CRT: Optimization of CRT increase the efficacy of the treatment Systematic AV-delay and VV-delay optimization of CRT (by SonR or echocardiography) generates an increase of 0,1 QALYs annually1,2 compared to those patients without systematic optimization 1: Kurt Banz. Cardiac resynchronization Therapy (CRT) in Heart Failure-Amodel to Assess Economoc Value of this New Medical Technology. Value in Heath; Volume 8- Number 2-2005; 128-139 2: Delnoy PP et al: Clear clinical study post hoc. Europace Advance Access published March 2013

  12. Comparison of CRT-D with standard optimization and CRT-D with SonR optimization vs optimal medical therapy: a simulation model proposed by Banz et al 2005 *OPT: optimal medical treatment ^cost of device included 1: Kurt Banz. Cardiac resynchronization Therapy (CRT) in Heart Failure-Amodel to Assess Economoc Value of this New Medical Technology. Value in Heath; Volume 8- Number 2-2005; 128-139

  13. Comparison of CRT-D with standard optimization and CRT-D with SonR optimization vs optimal medical therapy: a simulation model proposed by Banz et al 2005 Δ QALY Incremental cost- effectiveness ratio (ICER) = Cnew - Coll Effnew - Effold 14.900 € 0,32 QALY = Standard CRT-D Incremental cost- effectiveness ratio (ICER) = Cnew - Coll Effnew - Effold 15.058 € 0,52 QALY = CRT-D SonR

  14. Incremental cost- effectiveness ratio (ICER) = 15.058 € - 14.900 € 0,52 - 0,32 QALY = 790 €/QALY

  15. Sensitivity analysis of cost-effictiveness of CRT-D with SonR optimization vs Standard CRT-D: △ costs WTP

  16. Conclusions: • SonR optimization in CRT evaluated at 1 year of follow-up increases QALY by reducing hospitalization • The ICER of CRT-D with SonR vs CRT-D with standard optimization programming seems cost-effective • The evolution of the SonR algoritm with weekly optimization of pacing parameters, both at rest and on effort, might increase even further the responder percentage and increase cost-effectiveness

More Related